-
1
-
-
0028028308
-
Angiogenesis inhibition: a review. [Review] [436 refs]
-
10.1016/0163-7258(94)90027-2, 7530374
-
Auerbach W, Auerbach R. Angiogenesis inhibition: a review. [Review] [436 refs]. Pharmacol Ther 1994, 63:265-311. 10.1016/0163-7258(94)90027-2, 7530374.
-
(1994)
Pharmacol Ther
, vol.63
, pp. 265-311
-
-
Auerbach, W.1
Auerbach, R.2
-
2
-
-
0038687221
-
Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. [Review] [122 refs]
-
10.1016/S0361-090X(03)00030-8, 3384426, 22745585
-
Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. [Review] [122 refs]. Cancer Detection & Prevention 2003, 27:229-238. 10.1016/S0361-090X(03)00030-8, 3384426, 22745585.
-
(2003)
Cancer Detection & Prevention
, vol.27
, pp. 229-238
-
-
Bisacchi, D.1
Benelli, R.2
Vanzetto, C.3
Ferrari, N.4
Tosetti, F.5
Albini, A.6
-
3
-
-
0642377237
-
Antiangiogenesis: the fifth cancer treatment modality?. [Review] [61 refs]
-
10.1188/03.ONF.934-944, 14603351
-
Camp-Sorrell D. Antiangiogenesis: the fifth cancer treatment modality?. [Review] [61 refs]. Oncology Nursing Forum 2003, 30:934-944. 10.1188/03.ONF.934-944, 14603351.
-
(2003)
Oncology Nursing Forum
, vol.30
, pp. 934-944
-
-
Camp-Sorrell, D.1
-
4
-
-
0036951551
-
Antiangiogenesis agents. [Review] [69 refs]
-
10.1016/S0896-1549(02)00042-1, 12515077
-
Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA. Antiangiogenesis agents. [Review] [69 refs]. Ophthalmology Clinics of North America 2002, 15:453-458. 10.1016/S0896-1549(02)00042-1, 12515077.
-
(2002)
Ophthalmology Clinics of North America
, vol.15
, pp. 453-458
-
-
Ciardella, A.P.1
Donsoff, I.M.2
Guyer, D.R.3
Adamis, A.4
Yannuzzi, L.A.5
-
5
-
-
33644948640
-
Antiangiogenesis: a possible treatment option for prostate cancer?. [Review] [86 refs]
-
10.3816/CGC.2005.n.033, 16425989
-
Longoria RL, Cox MC, Figg WD. Antiangiogenesis: a possible treatment option for prostate cancer?. [Review] [86 refs]. Clinical Genitourinary Cancer 2005, 4:197-202. 10.3816/CGC.2005.n.033, 16425989.
-
(2005)
Clinical Genitourinary Cancer
, vol.4
, pp. 197-202
-
-
Longoria, R.L.1
Cox, M.C.2
Figg, W.D.3
-
6
-
-
0032240869
-
Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. [Review] [81 refs]
-
10.1007/978-3-642-45769-2_33, 9928571
-
Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. [Review] [81 refs]. Recent Results in Cancer Research 1998, 152:341-352. 10.1007/978-3-642-45769-2_33, 9928571.
-
(1998)
Recent Results in Cancer Research
, vol.152
, pp. 341-352
-
-
Harris, A.L.1
-
7
-
-
56049091266
-
Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model
-
Hu M, Yang JL, Teng H, Jia YQ, Wang R, Zhang XW, Wu Y, Luo Y, Chen XC, Zhang R, Tian L, Zhao X, Wei YQ. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. Bmc Cancer 2008, 8.
-
(2008)
Bmc Cancer
, vol.8
-
-
Hu, M.1
Yang, J.L.2
Teng, H.3
Jia, Y.Q.4
Wang, R.5
Zhang, X.W.6
Wu, Y.7
Luo, Y.8
Chen, X.C.9
Zhang, R.10
Tian, L.11
Zhao, X.12
Wei, Y.Q.13
-
8
-
-
79953330322
-
Antiangiogenesis enhances intratumoral drug retention
-
Ma J, Chen CS, Blute T, Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res 71:2675-2685.
-
Cancer Res
, vol.71
, pp. 2675-2685
-
-
Ma, J.1
Chen, C.S.2
Blute, T.3
Waxman, D.J.4
-
9
-
-
39049165334
-
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth
-
10.1158/0008-5472.CAN-07-3217, 18199548
-
Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008, 68:521-529. 10.1158/0008-5472.CAN-07-3217, 18199548.
-
(2008)
Cancer Res
, vol.68
, pp. 521-529
-
-
Ebos, J.M.1
Lee, C.R.2
Bogdanovic, E.3
Alami, J.4
Van Slyke, P.5
Francia, G.6
Xu, P.7
Mutsaers, A.J.8
Dumont, D.J.9
Kerbel, R.S.10
-
10
-
-
0036054742
-
Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. [Review] [97 refs]
-
Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. [Review] [97 refs]. Oncologist 2002, 3:4-11.
-
(2002)
Oncologist
, vol.3
, pp. 4-11
-
-
Conti, C.J.1
-
11
-
-
35448952213
-
Antiangiogenic agents: an update on small molecule VEGFR inhibitors. [Review] [194 refs]
-
2495
-
Schenone S, Bondavalli F, Botta M. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. [Review] [194 refs]. Curr Med Chem 14:2495-2516. 2495.
-
Curr Med Chem
, vol.14
, pp. 2495-2516
-
-
Schenone, S.1
Bondavalli, F.2
Botta, M.3
-
12
-
-
33144459287
-
VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. [Review] [80 refs]
-
1360224, 16146773
-
Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. [Review] [80 refs]. Front Biosci 2006, 11:818-829. 1360224, 16146773.
-
(2006)
Front Biosci
, vol.11
, pp. 818-829
-
-
Rahimi, N.1
-
13
-
-
34547152236
-
Antiangiogenesis, anti-VEGF(R) and outlook. [Review] [38 refs]
-
10.1007/978-3-540-46091-6_16, 17607926
-
Petersen I. Antiangiogenesis, anti-VEGF(R) and outlook. [Review] [38 refs]. Recent Results in Cancer Research 2007, 176:189-199. 10.1007/978-3-540-46091-6_16, 17607926.
-
(2007)
Recent Results in Cancer Research
, vol.176
, pp. 189-199
-
-
Petersen, I.1
-
14
-
-
34548443831
-
Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. [Review] [112 refs]
-
Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. [Review] [112 refs]. Cell Signal 2003, 19:2003-2012.
-
(2003)
Cell Signal
, vol.19
, pp. 2003-2012
-
-
Holmes, K.1
Roberts, O.L.2
Thomas, A.M.3
Cross, M.J.4
-
15
-
-
33748569487
-
Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin
-
10.1038/sj.cgt.7700958, 16799469
-
Wang R, Zhang XW, Wang GQ, Chen XC, Tian L, Yang HS, Hu M, Peng F, Yang JL, He QM, Zhang W, Jiang Y, Deng HX, Wen YJ, Li J, Zhao X, Wei YQ. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Cancer Gene Therapy 2006, 13:940-947. 10.1038/sj.cgt.7700958, 16799469.
-
(2006)
Cancer Gene Therapy
, vol.13
, pp. 940-947
-
-
Wang, R.1
Zhang, X.W.2
Wang, G.Q.3
Chen, X.C.4
Tian, L.5
Yang, H.S.6
Hu, M.7
Peng, F.8
Yang, J.L.9
He, Q.M.10
Zhang, W.11
Jiang, Y.12
Deng, H.X.13
Wen, Y.J.14
Li, J.15
Zhao, X.16
Wei, Y.Q.17
-
16
-
-
0029863730
-
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
-
1615
-
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615-1620. 1615.
-
Cancer Res
, vol.56
, pp. 1615-1620
-
-
Millauer, B.1
Longhi, M.P.2
Plate, K.H.3
Shawver, L.K.4
Risau, W.5
Ullrich, A.6
Strawn, L.M.7
-
17
-
-
67650337790
-
Development of bacterial vectors for tumor-targeted gene therapy. [Review] [108 refs]
-
10.1007/978-1-59745-561-9_7, 19565900
-
Jia LJ, Hua ZC. Development of bacterial vectors for tumor-targeted gene therapy. [Review] [108 refs]. Methods in Molecular Biology 2009, 542:131-154. 10.1007/978-1-59745-561-9_7, 19565900.
-
(2009)
Methods in Molecular Biology
, vol.542
, pp. 131-154
-
-
Jia, L.J.1
Hua, Z.C.2
-
19
-
-
78049436238
-
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
-
3953
-
Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 120:3953-3968. 3953.
-
J Clin Invest
, vol.120
, pp. 3953-3968
-
-
Chinnasamy, D.1
Yu, Z.2
Theoret, M.R.3
Zhao, Y.4
Shrimali, R.K.5
Morgan, R.A.6
Feldman, S.A.7
Restifo, N.P.8
Rosenberg, S.A.9
-
20
-
-
33646671508
-
Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. [Review] [23 refs]
-
10.2325/jbcs.13.27, 16518059
-
Fujimori M. Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. [Review] [23 refs]. Breast Cancer 2006, 13:27-31. 10.2325/jbcs.13.27, 16518059.
-
(2006)
Breast Cancer
, vol.13
, pp. 27-31
-
-
Fujimori, M.1
-
21
-
-
79956364212
-
Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion
-
10.1136/bjo.2010.192468, 21109696
-
Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 2011, 95:788-792. 10.1136/bjo.2010.192468, 21109696.
-
(2011)
Br J Ophthalmol
, vol.95
, pp. 788-792
-
-
Noma, H.1
Funatsu, H.2
Mimura, T.3
Eguchi, S.4
Shimada, K.5
-
22
-
-
18844382645
-
Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma
-
10.1111/j.1745-7254.2005.00094.x, 15842785
-
Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin 2005, 26:629-634. 10.1111/j.1745-7254.2005.00094.x, 15842785.
-
(2005)
Acta Pharmacol Sin
, vol.26
, pp. 629-634
-
-
Yi, C.1
Huang, Y.2
Guo, Z.Y.3
Wang, S.R.4
-
23
-
-
70349751825
-
[Cloning and prokaryotic expression of Bifidobacterium infantis-mediated sKDR and its effect on proliferation of vascular endothelial cells]. [Chinese]
-
Mao SH, Ji LL, Liu H, Xu YZ, Huang H, Huang Y, Yi C. [Cloning and prokaryotic expression of Bifidobacterium infantis-mediated sKDR and its effect on proliferation of vascular endothelial cells]. [Chinese]. Sichuan da Xue Xue Bao. Yi Xue Ban/Journal of Sichuan University. Medical Science Edition 2009, 40:784-786.
-
(2009)
Sichuan da Xue Xue Bao. Yi Xue Ban/Journal of Sichuan University. Medical Science Edition
, vol.40
, pp. 784-786
-
-
Mao, S.H.1
Ji, L.L.2
Liu, H.3
Xu, Y.Z.4
Huang, H.5
Huang, Y.6
Yi, C.7
-
24
-
-
66049084202
-
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo
-
November
-
Bo L, Xiao-Chun P, Zheng X-L. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer November 2009, 66(2):169-175.
-
(2009)
Lung Cancer
, vol.66
, Issue.2
, pp. 169-175
-
-
Bo, L.1
Xiao-Chun, P.2
Zheng, X.-L.3
-
25
-
-
1242314730
-
Precision of the fractionator from Cavalieri designs
-
10.1111/j.1365-2818.2004.01291.x, 14731303
-
Cruz-Orive LM. Precision of the fractionator from Cavalieri designs. J Microsc 2004, 213:205-211. 10.1111/j.1365-2818.2004.01291.x, 14731303.
-
(2004)
J Microsc
, vol.213
, pp. 205-211
-
-
Cruz-Orive, L.M.1
-
26
-
-
0025120720
-
Doppler ultrasound color flow imaging in the study of breast cancer; Preliminary findings
-
10.1016/0301-5629(90)90020-D, 2238263
-
Adler DD, Carson PL, Rubin JM, Q-R D. Doppler ultrasound color flow imaging in the study of breast cancer; Preliminary findings. Ultrasound Med Biol 1990, 16:553-559. 10.1016/0301-5629(90)90020-D, 2238263.
-
(1990)
Ultrasound Med Biol
, vol.16
, pp. 553-559
-
-
Adler, D.D.1
Carson, P.L.2
Rubin, J.M.3
Q-R, D.4
-
27
-
-
68249155377
-
Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice
-
Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. Bmc Cancer 2009, 9.
-
(2009)
Bmc Cancer
, vol.9
-
-
Liu, T.G.1
Huang, Y.2
Cui, D.D.3
Huang, X.B.4
Mao, S.H.5
Ji, L.L.6
Song, H.B.7
Yi, C.8
-
28
-
-
14044267657
-
Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas
-
10.1007/s11060-004-9163-5, 15719267
-
Wang M, Tang J, Liu S, Yoshida D, Teramoto A. Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol 2005, 71:3-7. 10.1007/s11060-004-9163-5, 15719267.
-
(2005)
J Neurooncol
, vol.71
, pp. 3-7
-
-
Wang, M.1
Tang, J.2
Liu, S.3
Yoshida, D.4
Teramoto, A.5
-
29
-
-
0032542528
-
Gene therapy strategies for tumor antiangiogenesis. [Review] [224 refs]
-
10.1093/jnci/90.4.273, 9486813
-
Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. [Review] [224 refs]. Journal of the National Cancer Institute 1998, 90:273-286. 10.1093/jnci/90.4.273, 9486813.
-
(1998)
Journal of the National Cancer Institute
, vol.90
, pp. 273-286
-
-
Kong, H.L.1
Crystal, R.G.2
-
30
-
-
67651120191
-
Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth
-
10.1038/cgt.2009.7, 19229287
-
Hu B, Kou L, Li C, Zhu LP, Fan YR, Wu ZW, Wang JJ, Xu GX. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Therapy 2009, 16:655-663. 10.1038/cgt.2009.7, 19229287.
-
(2009)
Cancer Gene Therapy
, vol.16
, pp. 655-663
-
-
Hu, B.1
Kou, L.2
Li, C.3
Zhu, L.P.4
Fan, Y.R.5
Wu, Z.W.6
Wang, J.J.7
Xu, G.X.8
-
31
-
-
15444379976
-
Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas
-
10.1038/sj.gt.3302432, 15616600
-
Kaliberov SA, Kaliberova LN, Buchsbaum DJ. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Gene Therapy 2005, 12:407-417. 10.1038/sj.gt.3302432, 15616600.
-
(2005)
Gene Therapy
, vol.12
, pp. 407-417
-
-
Kaliberov, S.A.1
Kaliberova, L.N.2
Buchsbaum, D.J.3
-
32
-
-
33749103965
-
Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors
-
10.1023/A:1010644217648, 3383288, 22745540
-
Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Research & Treatment 2001, 66:165-170. 10.1023/A:1010644217648, 3383288, 22745540.
-
(2001)
Breast Cancer Research & Treatment
, vol.66
, pp. 165-170
-
-
Yazawa, K.1
Fujimori, M.2
Nakamura, T.3
Sasaki, T.4
Amano, J.5
Kano, Y.6
Taniguchi, S.7
-
33
-
-
0018888153
-
Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration
-
Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 2061, 40:2061-2068.
-
(2061)
Cancer Res
, vol.40
, pp. 2061-2068
-
-
Kimura, N.T.1
Taniguchi, S.2
Aoki, K.3
Baba, T.4
-
34
-
-
0034032620
-
Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors
-
10.1038/sj.cgt.7700122, 10770636
-
Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Therapy 2000, 7:269-274. 10.1038/sj.cgt.7700122, 10770636.
-
(2000)
Cancer Gene Therapy
, vol.7
, pp. 269-274
-
-
Yazawa, K.1
Fujimori, M.2
Amano, J.3
Kano, Y.4
Taniguchi, S.5
-
35
-
-
0026149395
-
Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve
-
10.3168/jds.S0022-0302(91)78272-6, 1860970
-
Yasui H, MO. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1991, 74:1187-1195. 10.3168/jds.S0022-0302(91)78272-6, 1860970.
-
(1991)
J Dairy Sci
, vol.74
, pp. 1187-1195
-
-
Yasui, H.1
Ohwaki, M.2
-
36
-
-
0034032620
-
Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors
-
10.1038/sj.cgt.7700122, 10770636
-
Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000, 7:269-274. 10.1038/sj.cgt.7700122, 10770636.
-
(2000)
Cancer Gene Ther
, vol.7
, pp. 269-274
-
-
Yazawa, K.1
Fujimori, M.2
Amano, J.3
Kano, Y.4
Taniguchi, S.5
-
37
-
-
0037328974
-
Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth
-
10.1038/sj.cgt.7700530, 12536198
-
Xi L, Geng-Feng F, Yan-Rong F. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003, 10:105-111. 10.1038/sj.cgt.7700530, 12536198.
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 105-111
-
-
Xi, L.1
Geng-Feng, F.2
Yan-Rong, F.3
-
38
-
-
0031867648
-
Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
-
10.1006/excr.1998.4039, 9633524
-
Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998, 241:161-170. 10.1006/excr.1998.4039, 9633524.
-
(1998)
Exp Cell Res
, vol.241
, pp. 161-170
-
-
Roeckl, W.1
Hecht, D.2
Sztajer, H.3
Waltenberger, J.4
Yayon, A.5
Weich, H.A.6
|